2803421-14-7

3BP-3940 is a highly potent and selective peptide inhibitor of FAP that targets cancer-associated fibroblasts (CAFs) in the tumor microenvironment. 3BP-3940 can be labeled with radionuclides (such as Ga-68) for precise tumor imaging or Lu-177 for the development of targeted anticancer technologies. 3BP-3940 accumulates in tumor lesions and can be used to diagnose and inhibit various solid cancers and CAFs-related diseases[1][2].

RDC Peptide

[1] Greifenstein L, et al. 3BP-3940, a highly potent FAP-targeting peptide for theranostics-production, validation and first in human experience with Ga-68 and Lu-177. iScience. 2023 Nov 23;26 (12) :108541. DOI:10.1016/j.isci.2023.108541
[2] Kramer C S, et al. FAP-Peptidvermittelte Radiorezeptortherapie (PTRT) bei soliden Tumoren: erste klinische Erfahrungen mit dem 177Lu-, 225Ac-oder 90Y-markierten Peptid 3BP-3940[J]. Nuklearmedizin-NuclearMedicine, 2023, 62 (02) : V14.